3 People Have Gotten Cancer-Detecting Implants in Their Brains

Brain-computer interfaces once existed only in the realm of science fiction, used to control prosthetic limbs or communicate through thought. Now, they are being tested in human brains to detect and possibly prevent cancer—a milestone that underscores the rapid evolution of neural technology and its potential to revolutionize medicine.

A New Frontier in Brain Cancer Treatment

Coherence Neuro, a San Francisco-based startup with ties to Elon Musk’s Neuralink, has taken a significant step forward in the fight against brain tumors. The company recently conducted trials involving three patients undergoing surgery for brain tumor removal at the Royal Melbourne Hospital in Australia. During the procedure, a coin-sized implant was temporarily placed in the brain, staying for about 30 minutes before being removed. This brief but critical test marked a crucial safety milestone, paving the way for future long-term implants in patients with brain cancer.

The device, a brain-computer interface, is designed to detect the unique electrical signals emitted by tumors and deliver mild electrical stimulation to prevent their growth. This approach is grounded in the understanding that cancerous tissue has distinctive electrical properties, similar to how conditions like epilepsy and depression affect neural networks. Coherence Neuro’s CEO and cofounder, Ben Woodington, has emphasized that the brain is a complex network, and tumors can be thought of as disruptions in that system.

How the Technology Works

The implant is equipped with 16 thin threads that extend into the brain tissue, allowing it to monitor and interact with neural activity. Unlike current treatment methods, such as the Optune wearable device, which requires patients to shave their heads and carry a battery, Coherence’s implant is designed to be surgically placed during tumor resection. This makes it more convenient and less intrusive for patients.

  • The implant continuously monitors the brain, detecting early signs of tumor regrowth.
  • It can deliver customized electrical stimulation to interfere with the tumor’s growth.
  • A connected app allows patients to log symptoms and receive real-time feedback from clinicians.

Currently, glioblastoma patients undergo regular MRI scans, but the intervals between scans are not always sufficient to catch sudden tumor growth. Coherence’s device aims to provide real-time monitoring and early intervention, potentially giving doctors more time to act before a tumor becomes untreatable.

Looking Ahead

The company plans to initiate trials in 2025 involving patients with glioblastoma, focusing on long-term implantation and data collection. If successful, this technology could significantly improve the prognosis for one of the most aggressive forms of cancer, which currently has a five-year survival rate of less than 10 percent.

The collaboration with Neuralink and other leading neurosurgeons suggests that this is not an isolated effort but part of a broader movement in neurotech and oncology. As research continues, the line between treating neurological conditions and detecting cancer may blur further, opening new doors for medical innovation.

This development is a clear sign that the future of medicine is being shaped by the integration of advanced neural technologies. The path ahead is still uncertain, but the potential to detect and prevent brain cancer through implants marks a significant leap forward in the quest to understand and manipulate the human brain.